BackDiaMedica Therapeutics Overview

DiaMedica Therapeutics Other Current Liabilities

Latest other current liabilities for DMAC: $2.3M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$2.34M
51.36% YoYΔ $794000.00 vs prior year quarter

Peer average

Loading

DiaMedica Therapeutics Other Current Liabilities History

Loading

DiaMedica Therapeutics vs. peers: Other Current Liabilities Comparison

Loading

DiaMedica Therapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

DiaMedica Therapeutics (DMAC) FAQ

DiaMedica Therapeutics (DMAC) currently reports a other current liabilities of $2.3M as of March 2026. That compares with $1.5M in the prior-year period — up 51.4% year over year. Use the charts on this page to explore DiaMedica Therapeutics's other current liabilities history and peer comparisons.

DiaMedica Therapeutics's other current liabilities increased from $1.5M to $2.3M — a 51.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

DiaMedica Therapeutics reported $2.3M in other current liabilities as of March 2026. That compares with $1.5M in the prior-year period — up 51.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $2.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for DiaMedica Therapeutics, and consider following DMAC for alerts when major investors trade the stock.

DiaMedica Therapeutics is classified in the Healthcare sector. On other current liabilities, it currently shows $2.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DMAC with unrelated industries.